EVALUATION OF THE PROFILE OF ADVERSE EVENT NOTIFICATIONS FOR IVERMECTIN AND NITAZOXANIDE BEFORE AND DURING THE COVID-19 PANDEMIC. CIPEEX, [S. l.], v. 5, n. 2, p. 1–5, 2025. Disponível em: https://anais.unievangelica.edu.br/index.php/CIPEEX/article/view/12866. Acesso em: 20 jun. 2026.